← Back to Search

CATALYSTEM for Congenital Hip Dysplasia (CATALYSTEM Trial)

N/A
Waitlist Available
Research Sponsored by Smith & Nephew, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up preoperative, 6-weeks, 1-year, 2-years and 5 years post-operative
Awards & highlights

Summary

A Multi-Center Study in Patients Undergoing Total Hip Arthroplasty with the Smith+Nephew CATALYSTEM™ Primary Hip System. The purpose of the study is to assess safety and performance of the CATALYSTEM™ and to support product approval in global markets.

Eligible Conditions
  • Congenital Hip Dysplasia
  • Osteoarthritis
  • Avascular Necrosis
  • Arthritis
  • Total Hip Replacement
  • Rheumatoid Arthritis

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~preoperative, 6-weeks, 1-year, 2-years and 5 years post-operative
This trial's timeline: 3 weeks for screening, Varies for treatment, and preoperative, 6-weeks, 1-year, 2-years and 5 years post-operative for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
CATALYSTEM™ femoral stem implant survivorship 2 years post-operatively by stem type (collared/collarless)
Secondary study objectives
CATALYSTEM™ femoral stem implant survivorship rates by stem type (collard/collarless)
EuroQol 5-Dimension 5-Level Visual Analogue Scale (EQ-5D-5L VAS)
Hip Disability and Osteoarthritis Outcome Score, Junior (HOOS Jr)
+7 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: CATALYSTEMExperimental Treatment1 Intervention
Participants who have already received or are due to receive the CATALYSTEM Cementless Primary Hip System

Find a Location

Who is running the clinical trial?

Smith & Nephew, Inc.Lead Sponsor
167 Previous Clinical Trials
21,910 Total Patients Enrolled
Rachel JahnkeStudy DirectorSmith & Nephew, Inc.
1 Previous Clinical Trials
140 Total Patients Enrolled
~132 spots leftby Dec 2026